Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia encountered in clinical practice. AF patients exhibit increased risks for heart attacks, heart failure, hospitalization, and death. AF is increasing in prevalence, with up to 15.1M cases estimated annually by 2050 in the USA. This increase is in large part due to aging of the […]
Chemical collections and methods for rapid storage, retrieval and assay are vital for new drug discovery. LIMR Chemical Genomics Center’s (LCGC) large chemical collection covers a unique structural space not covered by other pharma or commercial libraries. LCGC has developed a variety of hardware and software solutions to enable efficient, low-cost drug screens directed to […]
Inflammatory bowel disease (IBD), which includes ulcerative colitis (UC) and Crohn’s disease, is a debilitating autoimmune condition that is clinically challenging to manage effectively. In the U.S., the CDC estimates that 1.3% of adults (about 3 million) have been diagnosed with IBD. Many IBD patients are diagnosed early in life. As a result of chronic […]
The microbial organism Borrelia burgdorferi causes the common infection termed Lyme disease. This infection is transferred to humans by deer ticks and is common in areas of North America and other countries where large deer populations are found. In the U.S., the CDC has estimated that up to 476,000 cases of Lyme disease were diagnosed […]
Human genetics studies have identified Bin1 as second only to ApoE as a risk factor for late-onset Alzheimer’s disease (LOAD). Neurology studies indicate that Bin1 binds and influences the turnover of tau as a likely mechanism in promoting LOAD risk. Lankenau Institute for Medical Research scientists developed a cell-penetrating Bin1 antibody that appears to promote […]
TechTransCo, LLC d/b/a L2C Partners (“L2C Partners”) is not a registered broker-dealer or a registered investment adviser. You understand that the business plans of the companies posted on this website are furnished for your personal, noncommercial, informational purposes only, and that the inclusion of any company’s business plan (a “Company Plan”) on this website does not constitute an offer to sell, or a recommendation to buy, sell, or hold, any security of that company. To the extent that any of the information contained in any Company Plan may be deemed to be an offer to sell securities or investment advice, such information is impersonal and not directed towards any specific person. You agree and acknowledge that you are responsible for your own investment decisions with respect to any security of a company whose Company Plan is posted on this website.
L2C Partners has not reviewed any Company Plan posted on this website, and does not represent or warrant that any such Company Plan is accurate, reliable, correct or complete. THE COMPANY PLANS ARE PROVIDED "AS IS," “WHERE IS” AND “WITH ALL FAULTS,” AND L2C PARTNERS MAKES NO WARRANTY WITH RESPECT TO ANY COMPANY PLAN OF ANY KIND, EXPRESS, IMPLIED OR STATUTORY, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF ACCURACY, COMPLETENESS, TIMELINESS, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NONINFRINGEMENT, AND EXPRESSLY DISCLAIMS ALL SUCH WARRANTIES.
YOU AGREE AND ACKNOWLEDGE THAT NEITHER L2C PARTNERS NOR ITS AFFILIATES, MEMBERS, MANAGERS, OFFICERS, EMPLOYEES, BUSINESS PARTNERS, ADVISORS OR AGENTS (THE “L2C PARTIES”) SHALL HAVE ANY LIABILITY (JOINTLY OR SEVERALLY) TO YOU OR TO ANY OTHER PERSON FOR THE ACCURACY, RELIABILITY, CORRECTNESS OR COMPLETENESS OF ANY SUCH COMPANY PLAN, OR FOR ANY LOSSES, DAMAGES, EXPENSES, CLAIMS, OBLIGATIONS OR LIABILITIES, INCLUDING, WITHOUT LIMITATION, INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL, EXEMPLARY OR PUNITIVE DAMAGES, INCLUDING LOST PROFITS (COLLECTIVELY, THE “EXCLUDED DAMAGES”), ARISING FROM OR RELATED TO YOUR OR ANY OTHER PERSON’S USE OF OR RELIANCE ON THE CONTENT OF ANY COMPANY PLAN, WHETHER OR NOT CHARACTERIZED IN NEGLIGENCE, TORT, CONTRACT, OR OTHER THEORY OF LIABILITY, EVEN IF ANY OF THE L2C PARTIES HAVE BEEN ADVISED OF THE POSSIBILITY OF OR COULD HAVE FORESEEN ANY OF THE EXCLUDED DAMAGES. IF ANY PORTION OF THIS DISCLAIMER IS HELD TO BE UNENFORCEABLE, THEN THE L2C PARTIES' LIABILITY WILL BE LIMITED TO THE FULLEST POSSIBLE EXTENT PERMITTED BY APPLICABLE LAW.